Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.44 |
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA9 | Q16790 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 4/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18668478 | 0.83 | P4HTM (0.52) | CA2CA1CA9CA12KDM4E | |
| SCHEMBL2304195 | 0.81 | MAPK1 (0.57) | CA2CA1CA9CA12KDM4E | |
| SCHEMBL17168943 | 0.80 | ALDH1A1 (0.40) | KDM4ESMN1; SMN2ALDH1A1KCNJ1 | |
| SCHEMBL12695185 | 0.79 | P4HTM (0.40) | KDM4ESMN1; SMN2ALDH1A1KCNJ1 | |
| SCHEMBL24614210 | 0.73 | CA2 (0.35) | CA2CA1CA9CA12CA5A | |
| SCHEMBL23145073 | 0.73 | CA2 (0.35) | CA2CA1CA9CA12CA5A | |
| SCHEMBL23145075 | 0.73 | CA2 (0.35) | CA2CA1CA9CA12CA5A | |
| SCHEMBL2118260 | 0.72 | PTGS2 (0.57) | CA2CA1CA9CA12CA5A | |
| SCHEMBL30566466 | 0.72 | PTGS2 (0.57) | CA2CA1CA9CA12CA5A | |
| SCHEMBL30753596 | 0.72 | ALDH1A1 (0.47) | CA2CA1CA9CA12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-115151253-B | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-116574099-A | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-115151253-A | Phosphodiesterase inhibitors and uses thereof | 南京征祥医药有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | ENPP1, ENPP3, PDE4A | CA2 3011/4885CA1 4735/4885CA9 4116/4885 |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | CA2 2126/4885CA1 4390/4885CA9 3638/4885 |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | CA2 2126/4885CA1 4390/4885CA9 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.